Drug Trial Radar · NCT05708950
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Mar 3, 2023
Primary completion
Oct 16, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- Kineta Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Feb 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern. The study sought to assess the safety of KVA12123 \[TBS-2025\] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.
Conditions
- Cancer
- Solid Tumor
- Melanoma
- Carcinoma
- Sarcoma
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colo-rectal Cancer
- Uterine Cancer
- Pancreatic Cancer
- Gastric Cancer
- Esophageal Cancer
- Thyroid Cancer
- Ovarian Cancer
- Kidney Cancer
- Head and Neck Cancer
Interventions
KVA12123 - Dose EscalationDrug
Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
KVA12123 Plus Pembrolizumab - Dose EscalationDrug
Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
KVA12123 - Dose ExpansionDrug
KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
KVA12123 Plus Pembrolizumab - Dose ExpansionDrug
KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Through study completion, an average of 1 year
- AEs related to study drugTime frame: Through study completion, an average of 1 year
- Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)Time frame: Through study completion, an average of 1 year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
UCLA Health (Santa Monica Cancer Care)
Santa Monica, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
Sarah Cannon Research Institute at Florida Cancer Specialists
Sarasota, Florida
University of Michigan
Ann Arbor, Michigan
Thomas Jefferson University
Philadelphia, Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.